Llwytho...
Moxetumomab Pasudotox: First Global Approval
Moxetumomab pasudotox-tdfk (LUMOXITI™), an anti CD22 recombinant immunotoxin, has been developed by MedImmune and its parent company AstraZeneca for the treatment of hairy cell leukaemia. The product, discovered at the National Cancer Institute, is an optimised version of immunotoxin CAT-3888. Moxet...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Drugs |
|---|---|
| Prif Awdur: | |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Springer International Publishing
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6323103/ https://ncbi.nlm.nih.gov/pubmed/30357593 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-018-1000-9 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|